# US 2016/0250181 A1 · Alternative ACT with Natural Botanical Active GRAS Ingredients for Treatment and Prevention of the ZIKA Virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250181 A1
- Document ID: US20160250181A1
- Status: Published application
- Kind: A1
- Application number: 15/148,522
- Filed: 2016-05-06
- Published: 2016-09-01
- Earliest claimed: 2011-10-25
- Assignees: U.S. Phytotherapy, Inc.
- Applicants: U.S. Phytotherapy, Inc.
- Inventors: Bob D. Rosen
- Web page: https://patentgrep.com/patent/US20160250181A1

## CPC

- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/365: Lactones
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 36/59: Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

An all-natural active ingredient herbal compositions and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin, derivatives of artemisinin, berberine, capsaicin and Tinospora Cordifolia. When formulated in a gel cap, the composition can consist of only artemisinin, berberine, capsaicin, and Tinospora cordifolia. A blended mixture and inert ingredients, such as selected excipient compounds, are mixed together with artemisinin, berberine, capsaicin, and Tinospora cordifolia and compressed to form a single pill, tablet, or capsule for the treatment of Zika virus. A tablet or pill for children is formulated to be chewable.

## Claims

### Claim 1

A composition of all all-natural herbal ingredients formulated for treatment of humans and animals exposed to Zika virus, comprising active botanical ingredients, in combination:
artemisinin and derivatives thereof;
berberine;
capsaicin; and
Tinospora Cordifolia, wherein the composition provides a preventative treatment for Zika virus disease.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition for human adults includes
approximately 25 to approximately 60 milligrams (mg) artemisinin;
approximately 175 to approximately 500 milligrams (mg) berberine;
approximately 150 to approximately 300 millligrams (mg) capsaicin; and
approximately 80 to approximately 175 milligrams (mg) Tinospora Cordifolia.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the composition for human adults includes
approximately 45 to approximately 55 milligrams (mg) artemisinin;
approximately 300 to 450 milligrams (mg) berberine;
approximately 200 to approximately 275 millligrams (mg) capsaicin; and
approximately 100 to approximately 150 milligrams (mg) Tinospora Cordifolia.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the composition for human adults includes
approximately 50 milligrams (mg) artemisinin;
approximately 400 milligrams (mg) berberine;
approximately 225 millligrams (mg) capsaicin; and
approximately 125 milligrams (mg) Tinospora Cordifolia.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the combination of active botanical ingredients,
the artemisinin and derivatives thereof;
the berberine;
the capsaicin; and
the Tinospora Cordifolia, are packaged in a gelatin capsule (gelcap).

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition includes at least one inert binding or delivery component selected from the group comprising: microcrystalline cellulose, stearic acid, silicon dioxide, calcium carbonate, magnesium stearate and croscarmellose sodium used when forming a compressed pill.

### Claim 7

A composition of active botanical ingredients for treating an adult patient in a single pill, tablet or capsule comprising, in combination:
artemisinin and derivatives thereof;
berberine;
capsaicin;
Tinospora Cordifolia; and
a blended mixture of up to approximately 400 mg of concentrate of black walnut (Juglans nigra) dry outer hull; approximately 500 mg of concentrate of organically grown wormwood (Artemisia absinthium) dry flower and leaf; approximately 150 mg of concentrate of Clove (Syzygium aronalicum) dry flower; and approximately 700 mg of fresh leaf organically grown Chinese wormwood (Artemisia annua), wherein the composition is useful for prevention of Zika virus.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the composition for human adults includes
approximately 25 to approximately 60 milligrams (mg) artemisinin;
approximately 175 to approximately 500 milligrams (mg) berberine;
approximately 150 to approximately 300 millligrams (mg) capsaicin; and
approximately 80 to approximately 175 milligrams (mg) Tinospora Cordifolia.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the composition for human adults includes
approximately 45 to approximately 55 milligrams (mg) artemisinin;
approximately 300 to 450 milligrams (mg) berberine;
approximately 200 to approximately 275 millligrams (mg) capsaicin; and
approximately 100 to approximately 150 milligrams (mg) Tinospora Cordifolia.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the composition for human adults includes
approximately 50 milligrams (mg) artemisinin;
approximately 400 milligrams (mg) berberine;
approximately 225 millligrams (mg) capsaicin; and
approximately 125 milligrams (mg) Tinospora Cordifolia.

### Claim 11 (depends on 1)

A method for making the composition of claim 1 for an adult patient in a single pill, tablet, capsule, gelcap, oral suspension, sublingual or transdermal patch, or any other therapeutic preparation comprising the steps of:
a) providing a mixer;
ai) selecting an amount of artemisinin from a range of approximately 25 mg to approximately 60 mg;
aii) selecting an amount of berberine from a range of approximately 175 mg to approximately 500 mg;
aiii) selecting an amount of capsaicin from a range of approximately 150 mg to approximately 300 mg;
aiiii) selecting an amount of Tinospora Cordifolia from a range of approximately 80 mg to approximately 175 mg;
b) mixing artemisinin, berberine, capsaicin, and Tinospora Cordifolia in the mixer to form mixture (I);
c) mixing at least one binding or delivery component with mixture (I) to form mixture (II);
d) filtering mixture (II) through at least one filter to form mixture (III);
e) placing mixture (III) in a granulator;
f) granulating mixture (III) in the granulator to produce granulated chips;
g) pressing the granulated chips into tablets (Mixture IV);
h) removing dust from the tablets by cleaning and vacuuming the tablets;
i) applying an enteric shell coating to the cleaned and vacuumed tablets;
j) heating and tumbling the coated tablets; and
k) packaging the heated and tumbled coated tablets in a package.

### Claim 12 (depends on 11)

The method for making the composition in claim 11, wherein the mixing step (b) further includes the steps of:
selecting approximately 25 to approximately 60 milligrams (mg) artemisinin;
selecting approximately 175 to approximately 500 milligrams (mg) berberine;
selecting approximately 150 to approximately 300 millligrams (mg) capsaicin; and
selecting approximately 80 to approximately 175 milligrams (mg) Tinospora Cordifolia.

### Claim 13 (depends on 12)

The method for making the composition in claim 12, wherein the mixing step (b) further includes the steps of:
selecting approximately 45 to approximately 55 milligrams (mg) artemisinin;
selecting approximately 300 to approximately 450 milligrams (mg) berberine;
selecting approximately 200 to approximately 275 millligrams (mg) capsaicin; and
selecting approximately 100 to approximately 150 milligrams (mg) Tinospora Cordifolia.

### Claim 14 (depends on 13)

The method for making the composition in claim 13, wherein the mixing step (b) further includes the steps of:
selecting approximately 25 to approximately 60 milligrams (mg) artemisinin;
selecting approximately 175 to approximately 500 milligrams (mg) berberine;
selecting approximately 150 to approximately 300 millligrams (mg) capsaicin; and
selecting approximately 80 to approximately 175 milligrams (mg) Tinospora Cordifolia.

### Claim 15 (depends on 13)

The method for making the composition in claim 13, wherein the mixing step (b) further includes the steps of:
selecting approximately 50 milligrams (mg) artemisinin;
selecting approximately 400 milligrams (mg) berberine;
selecting approximately 225 millligrams (mg) capsaicin; and
selecting approximately 125 milligrams (mg) Tinospora Cordifolia.

### Claim 16 (depends on 11)

The method for making the composition in claim 11, wherein the mixing step includes the step of:
selecting at least one binding or delivery component from the group comprising: microcrystalline cellulose, stearic acid, silicon dioxide, calcium carbonate, magnesium stearate and croscarmellose sodium.
